Specifically, your doctor will monitor your scans for amyloid-related imaging abnormalities (ARIA). This is because Leqembi treatment can cause ARIA. In fact, Leqembi has a boxed warning about the ...

But in just the past year and a half, two anti-amyloid drugs—lecanemab (Leqembi) and donanemab (Kisunla ... And remember that APOE e4 gene? Having two copies also boosts the risk of ARIA. So before ...

The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisai and Biogen’s Leqembi.

A second, somewhat less controversial, anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi ... serious ARIA subsequently died, two of whom were heterozygous APOE carriers ...

Close monitoring for amyloid-related imaging abnormalities (ARIA) is advised during the first 14 weeks of treatment. In September 2023, Japan’s Ministry of Health, Labour, and Welfare (MHLW) approved ...

Eisai has filed for approval of its Alzheimer’s disease therapy Leqembi in South Korea ... that seem to be more common in patients with ApoE ε4 mutations and among those taking anticoagulants ...